摘要
目的观察吉西他滨联合卡培他滨治疗蒽环类耐药性晚期乳腺癌的疗效与毒性反应。方法2003年6月～2006年3月应用吉西他滨联合卡培他滨治疗蒽环类药物耐药的晚期乳腺癌32例。结果CR4例，PR14例，SD8例，PD6例，总有效率（CR＋PR）56．2％。全组中位缓解期5个月（2-14个月）。主要毒性为骨髓抑制，胃肠道反应和手足综合征，其中骨髓抑制主要以白细胞减少为主，Ⅲ-Ⅳ度白细胞减少发生率18．7％。结论吉西他滨联合卡培他滨对蒽环类药物耐药的转移性乳腺癌有较好疗效，且毒性可以耐受。
Objective To observe the results of gemeitabine combined with capecitabine on anthracycline - resistant breast cancer. Methods From June 2003 to March 2005, 32 anthracycline resistant breast cancer patients were treated with gemcitabine combined with capecitabine with a median of 3courses per patient （range from 2 to 6 courses）. Results The overall effective rate was 56.2%. The median time of response duration was 5 months （from 2 to 14 months）. The main toxicity was myelosuppression with grade Ⅲ and Ⅳ neutropenia being in 18.7% of the patienets. Conclusion Gemcitabine in combination with capecitabine is effective in treatment of anthracycline - resistant metastatic breast cancer patients and the adverse reactions were tolerable to the majority of the patients.
出处
《中国热带医学》
CAS
2006年第12期2217-2218,共2页
China Tropical Medicine
关键词
乳腺癌
吉西他滨
卡培他滨
临床观察
Breast cancer
Gemcitabine
Capecitabine
Clinical observation
